Abstract:Background: Serine proteinase inhibitor A3 (SERPINA3) has been discovered in the pathogenesis of many human diseases, but little is known about the role of SERPINA3 in coronary artery disease (CAD). Therefore, we aim to determine its relationship with CAD and its function in the pathogenesis of atherosclerosis. Methods: In total 86 patients with CAD and 64 patients with non-CAD were compared. The plasma SERPINA3 levels were measured using ELISA. Logistic regression analysis and receiver-operating characteristic (ROC) analysis were performed to illustrate the association between plasma SERPINA3 levels and CAD. In vitro, real-time PCR (RT-PCR) and immunofluorescence staining were used to determine the expression of SERPINA3 in atherosclerotic plaques and their component cells. Then rat aortic smooth muscle cells (RASMCs) were transfected with siRNA to knock down the expression of SERPINA3 and human umbilical vein endothelial cells (HUVECs) were stimulated by SERPINA3 protein. EdU assay and scratch assay were used for assessing the capability of proliferation and migration. The cell signaling pathway was evaluated by western blot and RT-PCR. Results: Patients with CAD [104.4(54.5–259.2) μg/mL] had higher levels of plasma SERPINA3 than non-CAD [65.3(47.5–137.3) μg/mL] ( P = 0.004). After being fully adjusted, both log-transformed and tertiles of plasma SERPINA3 levels were significantly associated with CAD. While its diagnostic value was relatively low since the area under the ROC curve was 0.64 (95% CI: 0.55–0.73). Secreted SERPINA3 might increase the expression of inflammatory factors in HUVECs. Vascular smooth muscle cells had the highest SERPINA3 expression among the aorta compared to endothelial cells and inflammatory cells. The knockdown of SERPINA3 in RASMCs attenuated its proliferation and migration. The phosphorylated IκBα and its downstream pathway were inhibited when SERPINA3 was knocked down. Conclusions: Elevated plasma SERPINA3 levels were associated with CAD. SERPINA3 can increase inflammatory factors expression in HUVECs. It can regulate VSMCs proliferation, migration, and releasing of inflammatory factors through the NF-κB signaling pathway. Thus, SERPINA3 played a significant role in the pathogenesis of atherosclerosis.

Heterozygous SERPINA1 Defects and Their Impact on Clinical Manifestations of Patients with Predominantly Antibody Deficiencies

Compound Hemizygous Variants in SERPINA7 Gene Cause Thyroxine-Binding Globulin Deficiency

Quantification of circulating alpha-1-antitrypsin polymers associated with different SERPINA1 genotypes

Rare SERPINA1 variants leading to severe Alpha-1 Antitrypsin Deficiency

PiS and PiZ Alleles of SERPINA1 Gene Are Associated With Specific Variants of a BRD4‐Independent Enhancer

Identification and characterisation of eight novel SERPINA1 Null mutations

Clinical Manifestations and Gene Analysis of 18 Cases of Hereditary Protein S Deficiency

Causal and Synthetic Associations of Variants in the SERPINA Gene Cluster with Alpha1-Antitrypsin Serum Levels.

Haplotype-Aware Detection of SERPINA1 Variants by Nanopore Sequencing

Plasma Cell Deficiency in Human Subjects with Heterozygous Mutations in Sec61 Translocon Alpha 1 Subunit (SEC61A1).

SERPING1 mutation update: Mutation spectrum and C1 Inhibitor phenotypes

SERPING1 polymorphisms in polypoidal choroidal vasculopathy.

The Clinical and Immunological Features of Patients with Primary Antibody Deficiencies

SERPINA11 related novel serpinopathy – A perinatal lethal disorder

The broad spectrum of lung diseases in primary antibody deficiencies

Newly revealed variants of SERPINA3 in generalized pustular psoriasis attenuate inhibition of ACT on cathepsin G

Analysis of PROS1 mutations and clinical characteristics in three Chinese families with hereditary protein S deficiency

The Association and Pathogenesis of SERPINA3 in Coronary Artery Disease

A SEC61A1 variant is associated with autosomal dominant polycystic liver disease

Alpha-1 deficiency in severe asthma patients

Identification and characterization of two SERPINC1 mutations causing congenital antithrombin deficiency